Boston, MA 04/28/2014 (wallstreetpr) – Cerner Corporation (NASDAQ:CERN) expects the revenue in the second quarter of this financial year to be in the range of $790 to $830 million.
New collaborations
Claritas Genomics and Cerner Corp have decided to join forces to advance customized medicine by developing connectivity and tools that will integrate next generation sequence based diagnostic testing into better health care practice. The two companies will collaborate to develop a fast, scalable lab solution for molecular diagnostics that is suited to NGS workflows, which are even more complex and produce much more data than conventional molecular diagnostic tests.
Claritas will execute Cerner’s Millennium Helix solution as part of the starting phase of the project. Later it will join Cerner’s Reference Lab Network to enable seamless ordering and results return for other Reference Lab Network partners.
Medassets Inc and Cerner Corporation (NASDAQ:CERN) are working to expand the business relationship of both these parties. Knowledge constituents of MedAssets Claims Management solution will be integrated within the Cerner Patient Accounting solution to provide Cerner’s clients operational efficiencies, substantially enhanced claims processing workflow capacities and optimized payments.
The agreement is based upon the reseller agreement of the two companies, which allows Cerner Corporation (NASDAQ:CERN) to market MedAssets complete portfolio of Web based revenue cycle solutions. It also exhibits a bilateral commitment to provide interoperable solutions that would enable providers to quickly adopt the most advanced revenue cycle technology in support of improving the efficacy and effectiveness of the healthcare industry.
A health benefits company of the United States, WellPoint Inc., has selected Cerner Corp to collaborate with it on a project to test ICD-10 business continuity. As a selected Revenue Management supplier and electronic medical records (EMR) supplier, Cerner will carry out extensive ICD-9 to ICD-10 testing with WellPoint. This end to end testing will be done for a select set of clients.
Latest developments
Cerner Corporation (NASDAQ:CERN) has entered into a contract to purchase nearly 237 acres in the Three Trails Crossing region on the location of Bannister Mall that was formerly there. The purchase would be made subject to securing of suitable financial incentives and the completion of relevant due diligence activities. The company intends to utilize the space as a site to accommodate estimated growth. The terms of this deal are not known.
